Preclinical | Phase I–III | Product development | Public health | Total | |
---|---|---|---|---|---|
HIV | |||||
Funding 1997–2010 | £220,563,052 | £111,316,004 | £23,783,625 | £160,119,168 | £515,781,849 |
Citations 1997–2013 | 80,109 | 14,883 | 8,677 | 124,020 | 227,689 |
Pound per publication | £2,753 | £7,479 | £2,741 | £1,291 | £2,265 |
Tuberculosis | |||||
Funding 1997–2010 | £96,477,706 | £11,605,445 | £20,172,857 | £39,735,452 | £167,991,460 |
Citations 1997–2013 | 50,193 | 2,876 | 5,757 | 34,662 | 93,488 |
Pound per publication | £1,922 | £4,035 | £3,504 | £1,146 | £1,797 |
Malaria | |||||
Funding 1997–2010 | £202,459,316 | £9,920,472 | £12,839,850 | £156,302,225 | £381,521,863 |
Citations 1997–2013 | 77,157 | 5,792 | 4,115 | 47,561 | 134,625 |
Pound per publication | £2,624 | £1,713 | £3,120 | £3,286 | £2,834 |